liver transplantation recipients
Conditions
Interventions
Intravenous administration of carperitide by the central dose of 0.1ug/kg/min, which is modulated between 0.025 and 0.22ug/kg/min according to the reactive urination.
Dose up of conventional diuretics
up to 2mg/kg/day, pottassium canrenoate
up to 8mg/kg/day ) alone.
Sponsors
The Artificial Organ and Transplantation Division, Department of Surgery
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patient selection: Patients who present with the following findings despite the use of conventional diuretics (furocemide up to 0.4mg/kg/day and potassium canrenoate up to 4mg/kg/day) among those who fulfill the above conditions and agreed to participate; A.) Elevated serum creatinine more than oe equal to 1mg/dl compared to that of preoperative value. B.) Oliguria less than or equal to 1ml/kg/h within 3 days postoperatively (evaluated q6 hours).
Exclusion criteria
Exclusion criteria: Exclusion criteria 1) Patients on chronic hemo-dialysis. 2) Patients who required hemo-dialysis prior to transplantation. (Includes the use of continuous hemo-diafiltration for treating hepatic coma in fulminant hepatic failure) 3) Patients with underlying complications such as diabetes, hypertension, heart disease, hepatopulmonary syndrome, pulmonary hypertension etc. 4) Patients with renal disease other than hepatorenal syndrome. 5) Patients with contraindicated conditions for the use of studied agent such as pheochromocytoma, epilepsy, and right ventricle infarction. 6) Those that are considered ineligible by the participating physician.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The number (rate) of cases requiring induction of hemo-dialysis due to insufficient diuresis fulfilling the following criteria. 1)Serum creatinine of >6.0mg/dl 2)Oliguria(1ml/kg/hr)lasting over 6hours 3)Serum potassium of > 6.0mEq/l | — |
Secondary
| Measure | Time frame |
|---|---|
| 1)Body weight 2)Blood pressure, pulse rate, urine volume 3)Serum creatinine, urea nitrogen 4)Serum atrial natriuretic peptide, aldosterone, brain natriuretic peptide, cyclic GMP 5)Serum renin activity 6)Urine creatinine 7)Urine NAG 8)Urine L-FABP 9)creatinine clearance | — |
Countries
Japan
Contacts
Public ContactYasuhiko Sugawara
University of Tokyo Artificial Organ and Transplantation Division, Hepato-Biliary-Pancreatic Surgery Division, Departme
Outcome results
None listed